NEW YORK (GenomeWeb News) — Abbott today said it has extended a research partnership with Caprion Proteomics to identify and use cancer antibody targets.
The agreement grants Abbott exclusive rights for up to two years to 10 lung cancer targets that Caprion found.
The new agreement extends an alliance the companies struck three years ago in which Abbott and Caprion used Caprion’s CellCarta proteomics platform to evaluate cell-surface drug targets by comparing plasma membrane proteins in normal tissues and cancer tissues.
Specific financial terms of the agreement were not released.
“From day one, the partnership with Caprion has resulted in a series of potential therapeutic antibody targets,” said Abbott divisional vice president Stephen Fesik said in a statement.
The new agreement will grant more time to wrap up pre-clinical evaluation of the 10 targets Abbott chose, Fesik added.